{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T20:50:48Z","timestamp":1781383848847,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100001513","name":"Breast Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1245\/s10434-025-18695-7","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:35:07Z","timestamp":1763742907000},"page":"2267-2274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Surgeon Perspectives on Axillary Management Following Neoadjuvant Endocrine Therapy: Results from a Qualitative Substudy of the PELOPS Trial"],"prefix":"10.1245","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct02764541","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Anna","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Revette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Nava-Coulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto Metzger","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"2","key":"18695_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1804710.","journal-title":"N Engl J Med."},{"issue":"25","key":"18695_CR2","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2108873.","journal-title":"N Engl J Med."},{"issue":"1","key":"18695_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10549-021-06153-3","volume":"188","author":"KU Park","year":"2021","unstructured":"Park KU, Gregory M, Bazan J, et al. Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. Breast Cancer Res Treat. 2021;188(1):249\u201358. https:\/\/doi.org\/10.1007\/s10549-021-06153-3.","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"18695_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10549-020-05644-z","volume":"181","author":"JR Dietz","year":"2020","unstructured":"Dietz JR, Moran MS, Isakoff SJ, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020;181(3):487\u201397.","journal-title":"Breast Cancer Res Treat."},{"issue":"13","key":"18695_CR5","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1245\/s10434-019-07785-y","volume":"26","author":"A Weiss","year":"2019","unstructured":"Weiss A, Wong S, Golshan M, et al. Patterns of axillary management in Stages 2 and 3 hormone receptor-positive breast cancer by initial treatment approach. Ann Surg Oncol. 2019;26(13):4326\u201336. https:\/\/doi.org\/10.1245\/s10434-019-07785-y.","journal-title":"Ann Surg Oncol."},{"issue":"17","key":"18695_CR6","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/jco.2010.31.6950","volume":"29","author":"MJ Ellis","year":"2011","unstructured":"Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype\u2013ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342\u20139. https:\/\/doi.org\/10.1200\/jco.2010.31.6950.","journal-title":"J Clin Oncol."},{"key":"18695_CR7","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 4.2025 April 17, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"18695_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1748-5908-8-35","volume":"8","author":"SA Flottorp","year":"2013","unstructured":"Flottorp SA, Oxman AD, Krause J, et al. A checklist for identifying determinants of practice: a systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice. Implement Sci. 2013;8:35. https:\/\/doi.org\/10.1186\/1748-5908-8-35.","journal-title":"Implement Sci."},{"issue":"4","key":"18695_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/1049732316665344","volume":"27","author":"MM Hennink","year":"2017","unstructured":"Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017;27(4):591\u2013608. https:\/\/doi.org\/10.1177\/1049732316665344.","journal-title":"Qual Health Res."},{"key":"18695_CR10","volume-title":"Successful qualitative research a practical guide for beginners","author":"V Clarke","year":"2013","unstructured":"Clarke V, Braun V. Successful qualitative research a practical guide for beginners. California: Sage Publications Ltd; 2013."},{"key":"18695_CR11","doi-asserted-by":"publisher","DOI":"10.4135\/9781036234386","volume-title":"Qualitative methods for health research","author":"J Green","year":"2018","unstructured":"Green J, Thorogood N. Qualitative methods for health research. California: Sage Publications Ltd; 2018."},{"issue":"6","key":"18695_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u201375. https:\/\/doi.org\/10.1001\/jama.2011.90.","journal-title":"JAMA."},{"issue":"12","key":"18695_CR13","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7.","journal-title":"Lancet Oncol."},{"issue":"11","key":"18695_CR14","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1245\/s10434-019-07583-6","volume":"26","author":"SM Wong","year":"2019","unstructured":"Wong SM, Weiss A, Mittendorf EA, King TA, Golshan M. Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: a national cancer database analysis. Ann Surg Oncol. 2019;26(11):3517\u201325. https:\/\/doi.org\/10.1245\/s10434-019-07583-6.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"18695_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000530584","volume":"18","author":"M Balic","year":"2023","unstructured":"Balic M, Thomssen C, Gnant M, Harbeck N. St., Gallen Vienna. optimization of treatment for patients with primary breast cancer-a brief summary of the consensus discussion. Breast Care (Basel). 2023;18(3):213\u201322.","journal-title":"Breast Care (Basel)"},{"issue":"11","key":"18695_CR16","doi-asserted-by":"publisher","first-page":"7362","DOI":"10.1245\/s10434-024-15705-y","volume":"31","author":"A Weiss","year":"2024","unstructured":"Weiss A, Colugnati F, Mitchell M, et al. Contemporary axillary surgical management in patients with pathologically node positive disease after neoadjuvant chemotherapy: a survey of members of the American Society of breast surgeons. Ann Surg Oncol. 2024;31(11):7362\u201371. https:\/\/doi.org\/10.1245\/s10434-024-15705-y.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"18695_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11136-023-03538-3","volume":"33","author":"N Vrancken Peeters","year":"2024","unstructured":"Vrancken Peeters N, Kaplan ZLR, Clarijs ME, et al. Health-related quality of life (HRQoL) after different axillary treatments in women with breast cancer: a 1-year longitudinal cohort study. Qual Life Res. 2024;33(2):467\u201379. https:\/\/doi.org\/10.1007\/s11136-023-03538-3.","journal-title":"Qual Life Res."},{"issue":"9","key":"18695_CR18","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3390\/cancers17091482","volume":"17","author":"S Marin-Liebana","year":"2025","unstructured":"Marin-Liebana S, Llor P, Serrano-Garcia L, et al. Gene expression signatures for guiding initial therapy in ER+\/HER2-early breast cancer. Cancers (Basel). 2025;17(9):1482.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"18695_CR19","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1001\/jamaoncol.2021.2132","volume":"7","author":"T Sella","year":"2021","unstructured":"Sella T, Weiss A, Mittendorf EA, et al. Neoadjuvant endocrine therapy in clinical practice: a review. JAMA Oncol. 2021;7(11):1700\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2021.2132.","journal-title":"JAMA Oncol."},{"issue":"3","key":"18695_CR20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10549-022-06647-8","volume":"194","author":"T Sella","year":"2022","unstructured":"Sella T, Kantor O, Weiss A, et al. The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy. Breast Cancer Res Treat. 2022;194(3):663\u201372. https:\/\/doi.org\/10.1007\/s10549-022-06647-8.","journal-title":"Breast Cancer Res Treat."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18695-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:40:00Z","timestamp":1770900000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18695-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["18695"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18695-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AW has undertaken paid advisory board participation for AbbVie, Merck, and Myriad and has received honoraria from OncLive (MJH Lifesciences), Empire State Hematology & Oncology Society, and the Society of Breast Imaging. EAM has undertaken compensated service on scientific advisory boards for AstraZeneca, BioNTech, Merck, and Moderna; has undertaken uncompensated service on steering committees for Bristol Myers Squibb and Roche\/Genentech; has received speaker\u2019s honoraria and travel support from Merck Sharp & Dohme; has received institutional research support from Roche\/Genentech (via SU2C grant) and Gilead; research funding from Susan Komen for the Cure, for which she serves as a scientific advisor, and has undertaken uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. TAK has received speaker honoraria from Exact Sciences and has undertaken compensated service on the FES Steering Committee for GE Healthcare, on an advisory board role for Veracyte, and as faculty for PrecisCa cancer information service. OM-F has received speaker honoraria, consultancy\/advisory honoraria, and institutional research support from Pfizer (no personal payments or honoraria were received from Pfizer prior to the completion of this study); speaker honoraria from AstraZeneca and Libbs; consultancy\/advisory honoraria from Jazz Pharmaceuticals and Oncocl\u00ednicas; and institutional research support from F. Hoffmann-La Roche AG\/Genentech Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}